HB6610 amends chapter 89 of title 5 to impose specific payment and conduct rules for pharmacy benefit managers (PBMs) that administer prescription drug benefits under Federal Employee Health Benefit (FEHB) plans. The bill prescribes how in‑network pharmacies must be reimbursed for ingredient cost and dispensing fees, requires PBMs to apply manufacturer rebates at the point of sale to reduce patient cost‑sharing and remit the remaining rebate to the carrier, and bans a set of practices PBMs commonly use to steer business to affiliated pharmacies or reduce pharmacy reimbursements after adjudication.
The measure creates a new enforcement regime inside FEHB: civil monetary penalties for violations, caps on those penalties over rolling 10‑year windows, a remediation plan requirement for carriers after repeated violations, and a debarment path for chronically noncompliant PBMs. The amendments take effect one year after enactment, shifting contract and compliance obligations for carriers and PBMs serving federal employees and changing economics for community and affiliated pharmacies alike.
At a Glance
What It Does
Requires FEHB contracts to (1) reimburse in‑network pharmacies for ingredient cost equal to NADAC (or WAC if NADAC absent) plus up to 4% (capped at $50), (2) pay a professional dispensing fee equal to the State Medicaid dispensing fee, (3) apply manufacturer rebates at the point of sale to lower member copays and remit the remaining rebate to the carrier; and (4) prohibit steering, network‑exclusion practices, post‑claim reductions, and other PBM tactics that favor affiliates.
Who It Affects
Affects PBMs (and their affiliates), FEHB carriers that contract with PBMs, in‑network community pharmacies (including independents and chain stores), affiliated/mail‑order pharmacies owned by PBMs, and federal employees and retirees who receive prescription drug benefits under FEHB plans.
Why It Matters
This bill replaces negotiated pricing discretion inside FEHB with formulaic reimbursement and strict conduct rules while creating an OPM enforcement path including civil fines and debarment. For compliance officers and payers, it creates new mandatory payment calculations, reporting and inspection obligations, and an enforcement regime that could materially change PBM‑pharmacy economics.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill attaches a new subsection to 5 U.S.C. §8904 that conditions any FEHB plan contract on a set of concrete payment and conduct rules for PBMs. First, it prescribes how ingredient cost is calculated: the PBM must reimburse an in‑network pharmacy using the national average drug acquisition cost (NADAC) on the claim adjudication date, or wholesale acquisition cost (WAC) if NADAC is unavailable, and then add the lesser of 4% of that amount or $50.
Second, the bill requires PBMs to pay a professional dispensing fee that equals the Medicaid dispensing fee in the state where the pharmacy is located. Those two mechanics create a relatively predictable per‑claim payment floor across states and drugs.
On rebates and patient cost sharing, the bill forces PBMs to apply manufacturer rebates at the point of sale so patient coinsurance or copays are calculated on the net price (after rebate). The PBM must then remit the full rebate amount to the FEHB carrier, but may deduct only the portion of the rebate that reduced the beneficiary’s cost sharing.
That shifts how rebate flows are accounted for: carriers receive the economic benefit of rebates while beneficiaries see lower out‑of‑pocket costs immediately.The statute also enumerates a suite of prohibitions intended to block common PBM behaviors that divert volume to owned pharmacies. PBMs and affiliates may not steer or require members to use a specific pharmacy, advertise affiliates over other in‑network pharmacies, impose network design elements (credentialing, day‑supply limits, delivery method limits) that effectively exclude in‑network pharmacies, or induce manufacturers to restrict distribution to a small set of pharmacies.
PBMs also may not impose post‑adjudication adjustments or non‑claim fees that reduce a pharmacy’s reimbursement.Enforcement rests with the Office of Personnel Management (OPM). The bill creates a new §8902b authorizing OPM, after consulting the Attorney General, to impose $10,000 civil penalties per violation on PBMs and, in some cases, carriers.
It also sets per‑PBM and per‑carrier 10‑year caps on penalties, requires carriers to submit remediation plans after recurring violations, and provides a debarment trigger when a PBM accrues 10 penalties in 10 years. The bill defines expedited administrative hearing routes, judicial review in federal district court, and offsets for penalties against amounts the United States owes the sanctioned parties.
The Five Things You Need to Know
Ingredient reimbursement: PBMs must reimburse in‑network pharmacies using NADAC on the claim date (or WAC if no NADAC) plus the lesser of 4% of that amount or $50.
Dispensing fee: PBMs must pay a professional dispensing fee equal to the State Medicaid dispensing fee where the pharmacy is located.
Rebate passthrough at point of sale: PBMs must apply manufacturer rebates to reduce member copays/coinsurance at sale and remit the remaining rebate to the FEHB carrier (less the amount that reduced member cost sharing).
Civil penalties and caps: OPM may impose $10,000 per violation on PBMs (and on carriers under repeated enforcement); per‑PBM and per‑carrier total penalty caps apply over any 10‑year period ($100,000 cap per PBM per carrier; $50,000 per carrier).
Debarment trigger and timing: A PBM that accumulates 10 penalties in 10 years becomes subject to debarment from FEHB contracting, effective 90 days after the first penalty that begins that debarment sequence, subject to hearings and appeals.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Ingredient‑cost reimbursement formula
Requires PBMs to reimburse an in‑network pharmacy’s ingredient cost equal to NADAC on the day of adjudication, or WAC if NADAC is unavailable, plus the lesser of 4% of that amount or $50. Practically, this fixes the acquisition reimbursement floor to a publicly published price index (NADAC) and caps the percentage add‑on, reducing negotiated variability but leaving state‑level differences through index and WAC availability.
Professional dispensing fee tied to Medicaid
Mandates that PBMs pay a professional dispensing fee equal to the State Medicaid dispensing fee where the pharmacy is located. This imports state Medicaid practice into FEHB reimbursement, producing wide geographic variation in the per‑prescription fee and anchoring pharmacy compensation to a third‑party benchmark rather than private negotiation.
Rebate treatment and prohibitions on PBM conduct
Requires PBMs to apply manufacturer rebates at point of sale so beneficiary cost sharing reflects the net price, then remit rebates to the carrier minus the coinsurance/copay reduction. Concurrently the bill bans steering members to specific (including affiliated) pharmacies, advertising affiliates over other in‑network pharmacies, network design features that exclude in‑network pharmacies, inducements to manufacturers to limit distribution, and any post‑adjudication reductions or non‑claim fees that lower pharmacy reimbursements. These clauses are aimed at preventing vertical‑integration tactics and preserving community pharmacy access.
Civil monetary penalties and remediation
Creates a civil penalty regime: OPM (after consulting DOJ) may impose $10,000 per violation on PBMs and on carriers under specified repeat circumstances. The statute caps total penalties for a PBM per carrier and for carriers over 10‑year windows, requires carriers to submit remediation plans after a fifth penalty within 10 years, and authorizes OPM inspections to monitor compliance. The bill also prescribes procedures for collection, deduction from federal payments, and a six‑year statute of limitations for penalty initiation.
Debarment, hearings, and judicial review
Sets debarment rules: a PBM is barred from administering FEHB benefits if it accrues 10 or more civil penalties within a 10‑year period; debarment generally becomes effective 90 days after the first penalty that establishes the debarment sequence. The provision requires notice, an opportunity for an administrative hearing conducted outside the APA’s usual subchapter II process, and permits district court review (District of Columbia or where the party resides). It also provides for termination of debarment if penalties are overturned on appeal.
Contract compliance and one‑year implementation lag
Adds compliance with the new 8904(c) payment and conduct rules as a requirement for FEHB plans under section 8903a(b), and sets the effective date: all changes take effect one year after enactment, giving carriers and PBMs a 12‑month window to update contracts and compliance systems before the rules bind FEHB contracts.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal employees and retirees with FEHB coverage — They will see immediate reductions in out‑of‑pocket cost sharing when rebates apply at the point of sale, and gain protections that preserve local pharmacy access.
- Independent and in‑network community pharmacies — The reimbursement floor tied to NADAC/WAC plus a Medicaid‑level dispensing fee and protection from post‑claim clawbacks strengthens per‑claim revenue and reduces risk of being displaced by PBM affiliates.
- FEHB carriers and plan actuaries — Carriers receive rebate remittances (after the portion that reduced member cost sharing) and gain a clearer accounting trail for rebate flows, which may simplify benefit cost allocation and oversight.
Who Bears the Cost
- Pharmacy benefit managers (PBMs) and affiliated pharmacy chains — The law constrains pricing levers, limits ability to shift volume to owned pharmacies, bans post‑adjudication fees, and exposes PBMs to fines and debarment risk, all of which can reduce PBM margins.
- FEHB carriers — Carriers must monitor PBM compliance, develop and implement remediation plans after repeated violations, cooperate with OPM inspections, and may shoulder operational and administrative costs associated with these obligations and potential penalties.
- Office of Personnel Management — OPM gains expanded enforcement duties including inspections, hearings, and appeals management without an explicit funding stream in the text, meaning oversight will generate administrative burden and potential resource strain.
Key Issues
The Core Tension
The bill forces a trade‑off between protecting beneficiary access and pharmacy payment transparency on one hand, and preserving PBMs’ contracting and formulary tools to manage drug costs on the other. Mandated payment floors and bans on common PBM tactics shrink commercial flexibility to negotiate net prices and steer volume, which may reduce PBM excesses but could also raise plan costs or prompt alternative cost‑management responses.
The bill locks FEHB pharmacy reimbursements to formulaic benchmarks (NADAC/WAC plus a capped percentage) and a state Medicaid dispensing fee. That creates clarity but imports the limitations of those benchmarks: NADAC is not updated uniformly across all drug presentations, WAC can be well above acquisition costs for some generics, and Medicaid dispensing fees vary widely by state.
Combined, those choices could either under‑compensate pharmacies for certain low‑margin drugs or over‑compensate for others, with spillovers to plan premiums and formulary decisions.
Operationally, applying rebates at point of sale and remitting the remainder to carriers creates accounting and IT complexity. PBMs, carriers, and pharmacies will need synchronized definitions of ‘rebate,’ consistent timing for adjudication and remittance, and reconciliations across pharmacy claims and manufacturer rebate contracts.
The civil penalty ceiling structure (per‑PBM and per‑carrier caps over 10‑year periods) may be too modest relative to PBM revenues to deter systemic noncompliance; conversely, the debarment trigger (10 penalties in 10 years) and the 90‑day effective rule could prompt aggressive litigation to forestall debarment. Finally, prohibiting network design elements that ‘exclude’ pharmacies could conflict with legitimate utilization controls or accreditation standards that carriers and PBMs use to assure safety and cost‑effective dispensing.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.